November 18, 2026
Pfizer Inc. (NYSE: PFE) does not need artificial intelligence to discover its patent cliff. The calendar has that covered. What the drugmaker needs is for newer medicines to grow fast enough to replace sales lost as older drugs face…
Positive Phase 3 leukemia results, progress in Parkinson’s drug delivery and a $2.2 billion acquisition agreement put clinical differentiation back at the center of the healthcare investment case.
Biotechnology’s most persuasive sales pitch is not a larger addressable-market slide. It is evidence…
A Retinal Bet With Big-Pharma Muscle and Blackstone Financing
Johnson & Johnson (NYSE: JNJ) is putting substantial capital behind a straightforward proposition: better control of retinal disease, potentially with more time between treatments, would be worth bringing into its pharmaceutical portfolio. On…
With oral VK2735 entering Phase 3 and injectable trials fully enrolled, Viking Therapeutics (NASDAQ: VKTX) is building a broader case in weight management.
Viking Therapeutics (NASDAQ: VKTX) has strengthened two foundations of its obesity-drug investment story: the capital to advance its programs…
Clinical progress, a proposed U.S. research initiative and vaccine licensing economics strengthen the bull case.
Biotechnology investors are finding fresh reasons to look beyond the pandemic trade. Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX) and Merck (NYSE: MRK) rallied on October 9 as…
